Blog

The COVID-19 pandemic forced the clinical trials industry to accept and accelerate the use of digital health technologies.

With 350 million people affected worldwide, rare diseases represent a major unmet medical need. However, the timely recruitment of eligible participants is a challenge for any rare disease clinical trial.

Real world data offers an alternative approach to observational research, particularly to inform decisions on patient needs and preferences.

This blog is a condensed version of an ICON employee’s’ personal journey of courage and endurance.

In a recent podcast interview, ICON experts discuss the intricacies of CGT development, the solutions that will enable CGT development on a global basis, and the future of CGT clinical trials.

Clinical development can better satisfy the evidence needs of payers, and not incorporating the needs of payers early into trial designs risks the need to spend more money later on.

Biosimilar uptake in the US market has, until now, stood in stark contrast to that in the EU, which has led the way in biosimilar approvals and use since 2006.

The COVID-19 pandemic has presented an array of cybersecurity challenges. With no slowing down of the virus’s spread, hackers and other cyber criminals are continuing to seize opportunities to take advantage of vulnerable networks.

COVID-19 is affecting how clinical trials are managed, in terms of patient recruitment, patient care, data collection, analysis and safety reporting.

The key considerations that arise when using digital technology to support endpoint generation in clinical studies.

For IVD manufacturers, the emergence of a novel virus is challenging as the detection of such viruses require quickly developed, novel diagnostic solutions.

In the evidence-based era of medicine and decision-making, literature reviews offer a faster and more cost-efficient method to gather intelligence.

As the COVID-19 crisis continues to unfold, there is an immediate need for rapid diagnostic testing to identify and track people infected by or exposed to coronavirus.

Formulation studies require time, money and expertise, and the race to clinic and beyond may tempt drug companies, especially smaller ones, to take shortcuts that end up costing more later.

COVID-19 studies require new approaches to monitoring beyond the standard remote and on-site visits. This might include data analytics and remote monitoring using technology.

The respiratory devices market is witnessing enormous demands across the globe, resulting from the increased need for ventilators due to rising COVID-19 cases.

ICON's In-Home and Alternative Site Clinical Solutions teams continue to review support to clients, sites and regulatory agencies to reduce the impact of COVID-19.

The human brain is probably the most complex structure in the universe. It is therefore not surprising that clinical trials for CNS diseases pose various challenges.

The COVID-19 pandemic is of particular concern for cardiovascular and metabolic trials because the subjects recruited are typically older with underlying cardiovascular disease and/or diabetes.

Rapid progress in connectivity and technology is inspiring innovative clinical trial design.